1.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-04-C-0104, NCI-6233, 6233, NCT00079144
|
|
2.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2003-009, NCT00199901
|
|
3.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2002-013, CTN Trial No.: 2007/123, CTN-Protocol# LUD2002-013AMEND, NCT00518206
|
|
4.
|
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CPMC-IRB-13824, LUDWIG-LUD00-025, NCI-G02-2068, NCT00037037
|
|
5.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-03034, LUDWIG-LUD2002-014, NCT00066729
|
|
6.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-03047, LUDWIG-LUD2002-004, NCT00070070
|
|
7.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2002-005, NCT00106158
|
|
8.
|
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD 2001-003, NCT00112242
|
|
9.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2003-022;NYU05-120;CUMC9147, NCT00299728
|
|
10.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2006-001, MSKCC IRB# 07-152, NCT00616941
|
|
11.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000640517, RPCI-I-127008, I 127008, NCT00887796
|
|
12.
|
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 05-140, 1R01CA112198-01, NCT00819806
|
|
13.
|
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MCC-15383, 106566, NCI-P-8215, NCT01008527
|
Mobile | Español
